IX: Summary of Meta-Analyses of Therapies for Postmenopausal Osteoporosis

Endocrine Reviews (Impact Factor: 21.06). 09/2002; 23(4):570-8. DOI: 10.1210/er.2001-9002
Source: PubMed


This section summarizes the results of the seven systematic reviews of osteoporosis therapies published in this series [calcium, vitamin D, hormone replacement therapy (HRT), alendronate, risedronate, raloxifene, and calcitonin] and systematic reviews of etidronate and fluoride we have published elsewhere. We highlight the methodological strengths and weaknesses of the individual studies, and summarize the effects of treatments on the risk of vertebral and nonvertebral fractures and on bone density, including effects in different patient subgroups. We provide an estimate of the expected impact of antiosteoporosis interventions in prevention and treatment populations using the number needed to treat (NNT) as a reference. In addition to the evidence, judgements about the relative weight that one places on weaker and stronger evidence, attitudes toward uncertainty, circumstances of patients' and societal values or preferences will, and should, play an important role in decision-making regarding anti-osteoporosis therapy.

12 Reads
  • Source
    • "The fractures associated with osteoporosis cause physical disability, reduced quality of life and high mortality in the aging population [3,4]. Several therapeutic options are available for the treatment or prevention of osteoporosis [5,6], and some of these drugs were proven to be efficacious and safe in Taiwanese population studies [7-10]. Among the osteoporosis management factors, vitamin D plays an important role [11,12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Vitamin D is essential for calcium metabolism, Vitamin D deficiency can precipitate osteoporosis, cause muscle weakness and increase the risk of fracture. The aim of this study was to assess the prevalence of vitamin D inadequacy among non-supplemented postmenopausal women with osteoporosis and fragility fractures of the hip or vertebrae in Taiwan. Methods This multi-center, cross-sectional, observational study analyzed the vitamin D inadequacy [defined as 25(OH) D level less than 30 ng/mL] in Taiwanese postmenopausal osteoporotic patients who suffered from a low trauma, non-pathological fragility hip or vertebral fracture that received post-fracture medical care when admitted to hospital or at an outpatient clinic. Results A total of 199 patients were enrolled at 8 medical centers in Taiwan; 194 patients met the study criteria with 113 (58.2%) and 81 (41.8%) patients diagnosed with hip and vertebral fracture, respectively. The mean serum 25(OH) D level was 21.1 ± 9.3 ng/mL, resulting in a prevalence of vitamin D inadequacy of 86.6% of the patients. Conclusions High prevalence of vitamin D inadequacy across all age groups was found among non-supplemented women with osteoporosis and fragility hip or vertebral fracture in Taiwan.
    BMC Musculoskeletal Disorders 07/2014; 15(1):257. DOI:10.1186/1471-2474-15-257 · 1.72 Impact Factor
  • Source
    • "The methodological quality was evaluated independently by two reviewers (Lin and Ying) with Cochrane Collaboration's tool for assessing the risk of bias and showed in Table 2 [22]. Four trials [6, 7, 9, 10] described explicit adequately randomization, concealment of allocation assignment, proper blinding, and applying intention to treat analysis, which were low risk of bias [16, 17, 19, 20], while the other three trials with inexplicit randomization and inadequate blinding were considered moderate risk of bias [15, 18, 21]. The weighted kappa for the agreement on the trial quality between reviewers was 0.84 95% CI: (0.75–0.93). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose. The aim of this study was to directly compare the efficacy and the safety of the two agents for postmenopausal women. Methods/Principal Findings. Electronic databases were searched for relevant articles that met our predefined inclusion criteria. Seven randomized controlled trials (RCTs) involving 4054 women were identified and included. Although Aln was more effective than Rlx in increasing bone mineral density (BMD), no statistical differences were observed in reducing the risk of neither vertebral fractures (P = 0.45) nor nonvertebral fractures (P = 0.87) up to two-year followup. Aln reduced the risk of vasomotor (P = 0.006) but increased the risk of diarrhea compared to Rlx (P = 0.01). Our subgroup analysis further indicated the difference between Aln and Rlx in fracture risk and was not materially altered by the administration pattern, the age. The weekly strategy of Aln would further reduce the upper gastrointestinal (GI) disorders and might gain more bone mass increment at lumbar spine compared to its daily treatment. Conclusion. There was no evidence of difference of fracture risk reduction between Aln and Rlx. In addition, age did not obviously influence their relative antifracture efficacy. For Aln the weekly strategy would further reduce the upper GI disorders and gain more bone mass increment compared to the daily treatment. During clinical decision making, the patients' adherence and the related side-effects associated with both drugs should also be taken into account.
    International Journal of Endocrinology 01/2014; 2014(14):796510. DOI:10.1155/2014/796510 · 1.95 Impact Factor
  • Source
    • "Cost-effectiveness analyses between active comparators have started to appear in the osteoporosis literature, for example, for denosumab [98, 111], strontium ranelate [112], and zoledronic acid [113]. Indirect comparisons of efficacy between drugs are less robust because of different baseline characteristics of the populations studied and overlapping confidence intervals for the effect of treatment [114]. Such analyses should therefore be interpreted with great caution. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We review the various aspects of health technology assessment in osteoporosis, including epidemiology and burden of disease, and assessment of the cost-effectiveness of recent advances in the treatment of osteoporosis and the prevention of fracture, in the context of the allocation of health-care resources by decision makers in osteoporosis. This article was prepared on the basis of a symposium held by the Belgian Bone Club and the discussions surrounding that meeting and is based on a review and critical appraisal of the literature. Epidemiological studies confirm the immense burden of osteoporotic fractures for patients and society, with lifetime risks of any fracture of the hip, spine, and forearm of around 40 % for women and 13 % for men. The economic impact is also large; for example, Europe's six largest countries spent 31 billion on osteoporotic fractures in 2010. Moreover, the burden is expected to increase in the future with demographic changes and increasing life expectancy. Recent advances in the management of osteoporosis include novel treatments, better fracture-risk assessment notably via fracture risk algorithms, and improved adherence to medication. Economic evaluation can inform decision makers in health care on the cost-effectiveness of the various interventions. Cost-effectiveness analyses suggest that the recent advances in the prevention and treatment of osteoporosis may constitute an efficient basis for the allocation of scarce health-care resources. In summary, health technology assessment is increasingly used in the field of osteoporosis and could be very useful to help decision makers efficiently allocate health-care resources.
    Calcified Tissue International 03/2013; 93(1). DOI:10.1007/s00223-013-9724-8 · 3.27 Impact Factor
Show more


12 Reads